In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
Angewandte Chemie International Edition · 10.03.2025 · 64 (11)
DOI: 10.1002/anie.202421713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 07.01.2025. Verfasst von Shaowen Xie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu, 211198, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Precision Medicine. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: National Natural Science Foundation of China, "Double First Class" University project of China Pharmaceutical University, the Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs) hold immense promise for targeted protein degradation; however, challenges such as off‐target effects, poor drug‐likeness properties, and the “hook effect” remain. This study introduces Nano‐Click‐formed PROTACs (Nano‐CLIPTACs) for precise tumor protein degradation in vivo. Traditional PROTACs with high molecular weight were first divided into two smaller druglike precursors capable of self‐assembling to form functional PROTACs through a bioorthogonal reaction. Then, optimal CLIPTACs precursors ( W4 and Z2 ) were encapsulated individually into cyclic RGDfC‐peptide‐modified liposomes to prepare Nano‐CLIPTACs, enabling tumor‐targeted delivery and subsequent in situ self‐assembly to form PROTACs WZ42 within tumor cells. The degradation abilities of Nano‐CLIPTACs in vitro and in vivo were further verified using a key oncology target, anaplastic lymphoma kinase (ALK), validating the safety, efficacy and “anti‐hook effect” of this strategy. Overall, Nano‐CLIPTACs represent a critical step towards the clinical translation of PROTACs technology for precise targeted anti‐cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu, 211198, China.
- Center of Advanced Pharmaceuticals and Biomaterials, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu, 211198, China.
ORCID-Profile: Shaowen Xie, Hong Yao, Jinyi Xu, Shengtao Xu
Förderung
- National Natural Science Foundation of China
- "Double First Class" University project of China Pharmaceutical University
- the Postgraduate Research & Practice Innovation Program of Jiangsu Province
Zitieren
APA
Xie, S., Zhu, J., Peng, Y., Zhan, F., Zhan, F., He, C., Feng, D., Xie, J., Liu, J., Zhu, H., Yao, H., Xu, J., Su, Z., & Xu, S. (2025). In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy. Angewandte Chemie International Edition, 64(11). https://doi.org/10.1002/anie.202421713
Vancouver
Xie S, Zhu J, Peng Y, Zhan F, Zhan F, He C, et al. In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy. Angewandte Chemie International Edition. 2025;64(11). doi:10.1002/anie.202421713
BibTeX
@article{Xie2025,
author = {Xie, Shaowen and Zhu, Jingjie and Peng, Yihan and Zhan, Fangyi and Zhan, Feiyan and He, Chen and Feng, Dazhi and Xie, Jia and Liu, Jingyu and Zhu, Huajian and Yao, Hong and Xu, Jinyi and Su, Zhigui and Xu, Shengtao},
title = {In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {11},
doi = {10.1002/anie.202421713}
}
EUVIMED